A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 18, 2022

Primary Completion Date

September 1, 2023

Study Completion Date

December 21, 2023

Conditions
Lichen Sclerosus
Interventions
DRUG

Ruxolitinib cream

Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

DRUG

Vehicle cream

Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.

Trial Locations (14)

14224

Circuit Clinical, West Seneca

20037

The Centers For Vulvovaginal Disorders, Washington D.C.

27516

Unc Dermatology and Skin Cancer Center At Southern Village, Chapel Hill

33186

New Age Medical Research Corporation, Miami

35244

Cahaba Dermatology, Birmingham

43209

Bexley Dermatology, Bexley

44004

Apex Dermatology, Ashtabula

75390

University of Texas Southwestern Medical Center, Dallas

84107

University of Utah Health Care Midvalley Health Center Dermatology, Murray

85259

Mayo Clinic - Scottsdale, Scottsdale

92697

UC Irvine, Irvine

98105

Seattle Skin and Laser Clinic, Seattle

N2J 1C4

K. Papp Clinical Research, Waterloo

G1V 3M7

Clinique Rsf, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY